Voyager Therapeutics (NASDAQ: VYGR) reported Q1 EPS of ($0.47), $0.06 better than the analyst estimate of ($0.53). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $8.17 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.